JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264846

Human GNA13 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

GNA13 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Western blot - Human GNA13 knockout HeLa cell line (AB264846)
  • WB

Lab

Western blot - Human GNA13 knockout HeLa cell line (AB264846)

Lanes 1 - 2 : Merged signal (red and green). Green - ab128900 observed at 45 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37 kDa.

ab128900 was shown to react with GNA13 in wild-type HeLa cells in Western blot with loss of signal observed in GNA13 knockout cell line ab264846 (GNA13 knockout cell lysate ab257451). Wild-type HeLa and GNA13 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab128900 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-GNA13 antibody [EPR5436] (<a href='/en-us/products/primary-antibodies/gna13-antibody-epr5436-ab128900'>ab128900</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

GNA13 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human GNA13 knockout HeLa cell line (ab264846)

Predicted band size: 44 kDa

Observed band size: 45 kDa

false

Sanger Sequencing - Human GNA13 knockout HeLa cell line (AB264846)
  • Sanger seq

Unknown

Sanger Sequencing - Human GNA13 knockout HeLa cell line (AB264846)

Allele-2 : Insertion of the selection cassette in exon 2.

Sanger Sequencing - Human GNA13 knockout HeLa cell line (AB264846)
  • Sanger seq

Unknown

Sanger Sequencing - Human GNA13 knockout HeLa cell line (AB264846)

Allele-1 : Insertion of the selection cassette in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon 2

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264846-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264846 Human GNA13 knockout HeLa cell line", "number":"AB264846-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264846-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264846-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264846-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264846 Human GNA13 knockout HeLa cell line", "number":"AB264846-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264846-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264846 Human GNA13 knockout HeLa cell line", "number":"AB264846-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264846-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264846 Human GNA13 knockout HeLa cell line", "number":"AB264846-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
GNA13
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Quality control - STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

GNA13 also known as Gα13 is a member of the G12 family of G proteins. It has a molecular mass of approximately 44 kDa and functions as a guanine nucleotide-binding protein. This protein is important in transmitting signals from G protein-coupled receptors (GPCRs) to intracellular signaling pathways. GNA13 is widely expressed in various tissues including endothelial cells smooth muscle cells and the brain. The signaling capability of GNA13 is based on its ability to bind GTP and GDP functioning through a cycle of activation and inactivation.
Biological function summary

The role of G protein subunit GNA13 involves participating in critical cellular functions such as cytoskeletal reorganization cell migration and proliferation. It is an integral part of the G12/G13 subunits' complex which plays a role in controlling cell dynamics and morphology. Through these activities GNA13 contributes to the regulation of processes like embryonic development and tissue repair. Additionally it influences cell behavior through the RhoA pathway affecting actin cytoskeleton and cell shape changes.

Pathways

GNA13 interacts with a variety of important signaling systems. One primary pathway where GNA13 is active is the Rho signaling pathway where it activates RhoA leading to changes in the actin cytoskeleton. This pathway is necessary for cellular processes like adhesion and motility. Additionally GNA13 participates in the mitogen-activated protein kinase (MAPK) pathway influencing cellular proliferation. Through these pathways GNA13 is related to proteins such as RhoGEFs which act as guanine nucleotide exchange factors and MAPKs essential in transmitting mitogenic signals.

GNA13 has implications in cancer development and cardiovascular diseases. Its role in Rho signaling and cell motility can contribute to tumor progression and metastasis with alterations in its function linked to various cancers. Additionally in cardiovascular health GNA13's influence on vascular smooth muscle contraction can relate to conditions such as hypertension. Projecting its influence through RhoA GNA13's malfunction connects it to pathological changes within these disease contexts.

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. <p>1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.<br>2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.<br>3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.<br>4. Incubate the culture at 37°C incubator with 5% CO<sub>2</sub>. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.<br>5. Once confluent passage into an appropriate flask at a density of 2x10<sup>4</sup> cells/cm<sup>2</sup>. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.</p>

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com